Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why Are Some Restaurants Resisting Reservation Apps?

While there is little question that technology permeates the ways in which we do business, not everyone is keen to “keep up.” For example, although there are now restaurant apps and online reservation systems, many restaurants still do things the old-fashioned way, taking reservations by phone. With Big Hospitality reporting that “60% of consumers booking…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

While there is little question that technology permeates the ways in which we do business, not everyone is keen to “keep up.” For example, although there are now restaurant apps and online reservation systems, many restaurants still do things the old-fashioned way, taking reservations by phone. With Big Hospitality reporting that “60% of consumers booking a restaurant online do so on a smart phone,” one has to wonder why some restaurants would want to actually avoid such apps.

Some of the benefits of having online booking include the ability to make offers that would attract patrons during slower periods. Reservation apps can allow restaurants to offer off-hours specials to help even out the peaks and valleys. The reservation app ResDiary has a feature called ResDiary Off-Peak that allows restaurants to raise and lower prices throughout the day, based on how busy they are. This is basically responsive supply-and-demand at work.

Yet, as Big Hospitality notes, there is also the problem of no-shows. Because making a reservation is so easy, it’s easy to just flake out on the reservation as well. As a result, the number of reservation no-shows has skyrocketed. Which costs restaurants money.

We reached out to more than a dozen restaurants in the Dallas area to see how they are using this kind of technology, but among the four restaurants to comment—Afrah, Jörg’s Café Vienna, The Dinner Table, and Blue Sushi Sake Grill—not a single one claims to use reservation apps.

In the case of Jörg’s Café Vienna, which is only open for lunch and dinner Wednesday through Saturday, there is no problem with getting people through the door during off-peak hours, since there are no off-peak hours. The Dinner Table similarly is only open during lunch and dinner on weekdays, with longer hours Saturday and only lunch Sunday, so the primary benefit of online apps doesn’t exist for them. The Dinner Table does use GrubHub to have their food delivered, but if you want to make a reservation, you will have to call them.

What they all seem to agree on is that they believe requiring customers to call them to make their reservations makes the experience more personal. While younger people, who are more confident in the technology, don’t think twice about making online reservations, older customers aren’t always so sure their reservation was received. This implies that restaurants may vary in their usage of technology based on their perception of which age demographics they are attracting.

This also implies that as time goes on, even the holdouts will eventually end up using reservation apps. After all, young people don’t stay young forever—but their online habits will remain as they get older.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512